Rüdiger Göke

TL;DR: The molecular cloning of a cDNA for the GIP‐receptor from a human insulinoma λgt11 cDNA library showed high homology to the human glucagon‐like peptide 1 (GLP‐1) receptor which will aid in the understanding of incretin hormone's failure to exert its biological action at the pancreatic B‐cell in type II diabetes mellitus.

TL;DR: DUG is a novel homologous to eukaryotic translation initiation factor (eIF) 4G and binds to eIF4A presumably through MA3 domains and inhibits both intrinsic and extrinsic pathways of apoptosis.

TL;DR: A slight but not dose-dependent stimulation of insulin secretion by supramaximal GLP-1 loads under basal glucose levels was found, but the necessary GLp-1 concentrations to achieve this in vitro effect are beyond physiological or postprandial levels.

TL;DR: The translation inhibitor pdcd4 represses endocrine tumor cell growth by suppression of carbonic anhydase II, and might represent promising tools for anti-endocrine tumor treatment.

TL;DR: It is concluded that tissue-specificity for GLP-1 receptors is based upon posttranslational modifications of the receptor protein (for example glycosilation) or alternative splicing of primary transcripts and not on variations within the coding sequence of the receptors gene.